Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ferring Pharmaceuticals
Public Company Edition: Three companies postponed or withdrew their offerings, but drug developers continue to pursue IPOs. Also, Biocon, BMS and Epizyme raised money through new debt, Five Prime capitalized on positive data and Synthetic Biologic engaged a strategic advisor.
NIH’s National Cancer Institute licensed two experimental cancer therapies in the past month to biopharma firms, leading a heavy slate of cancer-focused tech transfer deal-making.
Masimo’s planned buyout of Lidco could help expand its footprint into the US.
Following a strategic review, AMAG goes to Covis. Vincera goes public in merger with blank check company, has pending cancer deal with Bayer.
- Specialty Pharmaceuticals
- Drug Discovery Tools
- Other Names / Subsidiaries
- BioSurface Engineering Technologies, Inc. (BioSET)
- Cytokine PharmaSciences, Inc. (Subsidiary: Controlled Therapeutics Ltd.)
- Ferring Pharmaceuticals
- Rebiotix, Inc.